Новые технологии в профилактике и лечении сахарного диабета 1 типа
https://doi.org/10.18705/2311-4495-2014-0-4-5-10
Аннотация
Сахарный диабет 1А типа (СД1) является аутоиммунным заболеванием, характеризующимся деструкцией бета-клеток с развитием абсолютной инсулиновой недостаточности. Единственным эффективным способом терапии СД1 в настоящий момент является пожизненная заместительная инсулинотерапия. К сожалению, успешных методов профилактики и лечения СД1 в настоящий момент не существует. В данном обзоре будут рассмотрены результаты наиболее современных исследований по первичной, вторичной и третичной профилактике СД1.
Ключевые слова
сахарный диабет,
профилактика,
бета-клетка,
инсулин,
diabetes mellitus,
prevention,
beta-cell,
insulin
Об авторах
Елена Николаевна Гринёва
ФГБУ «Федеральный медицинский исследовательский центр им. В.А. Алмазова» Минздрава России
Россия
Россия
Екатерина Никодимовна Кравчук
ФГБУ «Федеральный медицинский исследовательский центр им. В.А. Алмазова» Минздрава России
Россия
Россия
Список литературы
1. Yoon J.W., Jun H.S. Cellular and molecular pathogenic mechanisms of insulin-dependent diabetes mellitus / Ann. N.Y. Acad Sci. - 2001. - Vol. 928. - P. 200-211.
2. Achenbach P., Bonifacio E., Koczwara K. et al. Natural history of type 1 diabetes / Diabetes. - 2005. - Vol. 54. - P. 25-31.
3. Bluestone J.A., Herold K., Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes / Nature. - 2010. - Vol. 29, № 464. - P. 1293-1300.
4. Skyler J.S. Primary and secondary prevention of Type 1 diabetes / Diabet. Med. - 2013. - Vol. 30, № 2. - P. 161-169.
5. Gerstein H.C. Cow’s milk exposure and type I diabetes mellitus. A critical overview of the clinical literature / Diabetes Care. - 1994. - Vol. 17. - P. 13-19.
6. Virtanen S.M., Bärlund S., Salonen M. et al. Feasibility and compliance in a nutritional primary prevention trial in infants at increased risk for type 1 diabetes / Acta Paediatr. - 2011. - Vol. 100, № 4. - P. 557-564.
7. TRIGR Study Group. Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR) / Pediatr. Diabetes. - 2007. - Vol. 8. - P. 117-137.
8. Vaarala O., Ilonen J., Ruohtula T. et al. Removal of bovine insulin from cow’s milk formula and early initiation of beta-cell autoimmunity in the FINDIA pilot study / Arch. Pediatr. Adolesc. Med. - 2012. - Vol. 166. - P. 608-614.
9. Zipitis C.S., Akobeng A.K. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis / Arch. Dis. Child. - 2008. - Vol. 93. - P. 512-517.
10. Schmid S., Buuck D., Knopff A. et al. BABYDIET, a feasibility study to prevent the appearance of islet autoantibodies in relatives of patients with type 1 diabetes by delaying exposure to gluten / Diabetologia. - 2004. - Vol. 47. - Р. 1130-1131.
11. Chase H.P., Lescheck E., Rafkin-Mervis L. et al. Nutritional intervention to prevent (NIP) type 1 diabetes: a pilot trial / Infant. Child. Adolesc. Nutr. - 2009. - Vol. 1. - P. 98-107.
12. Achenbach P., Barker J., Bonifacio E., Pre-POINT Study Group. Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization / Curr. Diab. Rep. - 2008. - Vol. 8, № 2. - P. 87-93.
13. Lazarow A. Protection against alloxan diabetes / Anat. Rec. - 1947. - Vol. 97. - P. 353.
14. Dulin W.E., Wyse B.M. Studies of ability of compounds to block the diabetogenic activity of streptozotocin / Diabetes. - 1969. - Vol. 18. - P. 459-466.
15. Yamada K., Nonaka K., Hanafusa T. et al. Preventive and therapeutic aspects of large dose nicotinamide injections on diabetes associated with insulitis: an observation in non-obese diabetic (NOD) mice / Diabetes. - 1982. - Vol. 31. - P. 749-753.
16. Elliott R.B., Pilcher C.C., Stewart A. et al. The use of nicotinamide treatment in the prevention of type 1 diabetes / Ann. NY Acad. Sci. - 1993. - Vol. 696. - P. 333-341.
17. Lampeter E.F., Klinghammer A., Scherbaum W.A. et al. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group / Diabetes. - 1998. - Vol. 47. - P. 980-984.
18. European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomized controlled trial of intervention before the onset of type 1 diabetes / Lancet. - 2004. - Vol. 363. - P. 925-931.
19. Diabetes Prevention Trial - Type 1 Study Group. Effects of insulin in relatives of patients with Type 1 diabetes mellitus / N. Engl. J. Med. - 2002. - Vol. 346. - P. 1685-1691.
20. Thrower S.L., James L., Hall W. et al. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-inman Phase I safety study / Clin. Exp. Immunol. - 2009. - Vol. 155. - P. 156-165.
21. NCT01122446. Diabetes Prevention - Immune Tolerance (DIAPREV-IT) / [Электронный ресурс]. URL: http://www.ClinicalTrials.gov (December 2012).
22. Carel J.C., Boitard C., Eisenbarth G. et al. Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre-type 1 diabetic children / J. Autoimmun. - 1996. - Vol. 9. - P. 739-745.
23. NCT 01030861. Teplizumab for prevention of Type diabetes in relatives ‘at-risk’ / [Электронный ресурс]. URL: http://www.ClinicalTrials.gov (дата обращения: 12.12.2012).
24. Assan R., Feutren G., Debray-Sachs M. et al. Metabolic and immunological effects of cyclosporine in recently diagnosed type 1 diabetes mellitus / Lancet. - 1985. - Vol. 1. - P. 67-71.
25. Stiller C., Dupré J., Gent M. et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset / Science. - 1984. - Vol. 223. - P. 1362-1367.
26. Bougneres P.F. , Landais P., Boisson C. et al. Limited duration of remission of insulin dependency in children with recent overt type 1 diabetes treated with low-dose cyclosporin / Diabetes. - 1990. - Vol. 39. - P. 1264-1272.
27. Skyler J.S., Ricordi C. Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man / Diabetes. - 2011. - Vol. 60, № 1. - P. 1-8.
28. Sherry N., Hagopian W., Ludvigsson J. et al. Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomized placebocontrolled trial / Lancet. - 2011. - Vol. 378. - P. 487-497.
29. Orban T., Bundy B., Becker D.J. Type 1 Diabetes TrialNet Abatacept Study Group. Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment / Diabetes Care. - 2014. - Vol. 37, № 4. - P. 1069-1075.
30. Voltareli J.C., Couri C.E.B., Stracieri A.B.P.L. et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus / JAMA. - 2007. - Vol. 297. - P. 1568-1576.
31. Couri C.E.B., Oliveira M.C.B., Stracieri A.B.P.L. et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus / JAMA. - 2009. - Vol. 301. - P. 1573-1579.
32. Leal A.M.O., Oliveira M.C., Couri C.E.B. et al. Testicular function in patients with type 1 diabetes treated with high-dose CY and autologous hematopoietic SCT / Bone Marrow Transplant. - 2012. - Vol. 47. - P. 467-468.
33. Ludvigsson J., Faresjö M., Hjorth M. et al. GAD treatment and insulin secretion in recent-onset Type 1 diabetes / N. Engl. J. Med. - 2008. - Vol. 359, № 18. - P. 1909-1920.
34. Wherrett D.K., Bundy B., Becker D.J. et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset Type 1 diabetes: a randomised double-blind trial / Lancet. - 2011. - Vol. 378, № 9788. - P. 319-327.
35. Ludvigsson J., Krisky D., Casas R. et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus / N. Engl. J. Med. - 2012. - Vol. 366. - P. 433-442.
36. Raz I., Elias D., Avron A. et al. Beta-cell function in new-onset Type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, Phase II trial / Lancet. - 2001. - Vol. 358. - P. 1749-1753.
37. Schloot N.C., Meierhoff G., Lengyel C. et al. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus Type 1: two prospective, randomized, double-blind Phase II trials / Diabetes Metab. Res. Rev. - 2007. - Vol. 23, № 4. - P. 276-285.
38. Raz I., Ziegler A.G., Linn T. Treatment of Recent-Onset Type 1 Diabetic Patients With DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial / Diabetes Care. - 2014. - Vol. 37, № 5. - P. 1392-1400.
Рецензия
Для цитирования:
Гринёва Е.Н., Кравчук Е.Н. Новые технологии в профилактике и лечении сахарного диабета 1 типа. Трансляционная медицина. 2014;(4):5-10. https://doi.org/10.18705/2311-4495-2014-0-4-5-10
For citation:
Grineva E.N., Kravchuk E.N. NEW TECHNOLOGIES IN PREVENTION AND TREATMENT OF DIABETES TYPE 1. Translational Medicine. 2014;(4):5-10. (In Russ.) https://doi.org/10.18705/2311-4495-2014-0-4-5-10
Просмотров: 405
Послать статью по эл. почте 